Related Experiment Videos
Homogeneous Cell- and Bead-Based Assays for High Throughput Screening Using Fluorometric Microvolume Assay
Miraglia1, Swartzman, Mellentin-Michelotti
1PE Biosystems, Foster City, CA.
Journal of Biomolecular Screening
|June 6, 2000
Summary
Fluorometric microvolume assay technology (FMAT) offers a nonradioactive, miniaturized solution for high throughput drug screening. This fluorescence-based platform enables homogeneous assays, streamlining the drug discovery process.
Area of Science:
- Biochemistry
- Assay Development
- Drug Discovery
Background:
- High throughput screening (HTS) is essential for modern drug discovery.
- Miniaturization and nonradioactive formats are key requirements for HTS assays.
- Homogeneous assays reduce automation needs, improving efficiency.
Purpose of the Study:
- To introduce Fluorometric Microvolume Assay Technology (FMAT) as a novel platform for HTS.
- To demonstrate the versatility and applicability of FMAT in various assay formats.
- To highlight the advantages of FMAT for drug screening.
Main Methods:
- FMAT utilizes a fluorescence-based, laser scanning system to image microwell plates.
- The technology detects localized fluorescence from cells or beads at the bottom of wells.
- Data processing ignores unbound fluorophore, enabling homogeneous assay development.
Main Results:
- FMAT is compatible with various assay types, including ligand binding, immunofluorescence, apoptosis, cytotoxicity, and bead-based assays.
- The system is plate format-independent and integrates with robotic automation for unattended operation.
- Localized fluorescence detection allows for sensitive and specific assay results.
Conclusions:
- FMAT provides a robust, nonradioactive, and miniaturized solution for HTS.
- The technology supports a wide range of homogeneous assays, enhancing drug discovery efficiency.
- FMAT is a valuable tool for developing and implementing advanced drug screening platforms.